Cover Image
市場調查報告書

全球PVA(停經後陰道萎縮)治療藥市場

Global PVA Drugs Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 301113
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
全球PVA(停經後陰道萎縮)治療藥市場 Global PVA Drugs Market 2014-2018
出版日期: 2014年04月25日 內容資訊: 英文 58 Pages
簡介

陰道委縮定義為雌激素產生低下。雌激素的減少使陰道細胞變薄,乾燥及彈性降低。PVA定義為停經後的雌激素降低。停經後的女性最大40%有萎縮性陰道炎的症狀。PVA的症狀為皮膚發紅、發熱、搔癢、乾燥、焦躁及性交疼痛。PVA的治療使用HRT,雌激素軟膏及其他的外用製劑。全球PVA(停經後陰道萎縮)治療藥市場,預計從2013年到2018年之間,以7.1%的年複合成長率擴大。

本報告提供全球PVA(停經後陰道萎縮)治療藥市場趨勢與成長預測、市場成長因素和課題、主要供應商分析等等,為您概述為以下內容。

第1章 摘要整理

第2章 詞彙表

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場分析技術

  • 市場分析的流程
  • 分析方法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場的規模與預測
  • 美國的PVA治療藥市場
    • 市場規模與預測
  • 歐洲的PVA治療藥市場
    • 市場規模與預測
  • 波特的五力分析

第7章 競爭分析:上市藥

第8章 管線欄概要

第9章 發病率、得病率

第10章 市場區隔:各類型

  • 外用雌激素
    • 陰道軟膏
    • 陰道片劑
    • 避孕環
  • 滲透性雌激素
    • 口服雌激素

第11章 地區區分

第12章 購買標準

第13章 市場成長的促進要素

第14章 促進成長要素與其影響

第15章 市場課題

第16章 促進成長要素與課題的影響

第17章 市場趨勢

第18章 市場趨勢與其影響

第19章 業者情勢

  • 競爭方案
    • 主要消息
    • M&A
  • 市場佔有率分析
  • 其他有潛力的供應商

第20章 主要供應商分析

  • Pfizer Inc.
    • 產業概要
    • 產業區分
    • 主要資訊
    • SWOT分析
  • Shionogi & Co. Ltd.
  • Novo Nordisk A/S
  • Actavis plc

第21章 相關報告

圖表一覽

目錄
Product Code: IRTNTR3488

About PVA Drugs

Vaginal atrophy is defined as decrease in estrogen production. Less estrogen leads to thinning, drying, and decreased elasticity of the vaginal tissues. PVA is defined as the decrease in estrogen after the menopause. Up to 40 percent of postmenopausal women have symptoms of atrophic vaginitis. In PVA there are symptoms of redness, burning, itching, dryness, irritation, and dyspareunia. HRT, estrogen creams, and other topical preparations are used in the treatment of PVA.

TechNavio's analysts forecast the Global PVA Drugs market will grow at a CAGR of 7.1 percent over the period 2013-2018.

Covered in this Report

The Global PVA Drugs market can be divided into two segments: Topical Estrogen and Systemic Estrogen. To calculate the market size, the report considers the revenue generated from the sales of various drugs (creams, tablets, and rings) used in the treatment of PVA.

TechNavio's report, the Global PVA Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global PVA Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Actavis plc
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Shionogi & Co. Ltd.

Other Prominent Vendors

  • ANI Pharmaceuticals Inc.
  • Bionovo Inc.
  • EndoCeutics Inc.
  • QuatRx Pharmaceutical Co.
  • PeP-Tonic Medical AB
  • Teva Pharmaceutical Industries Ltd.
  • Therapeutics MD Inc.
  • Upsher-Smith Laboratories Inc.

Market Driver

  • Significant Unmet Need.

For a full, detailed list, view our report.

Market Challenge

  • Increasing Number of Patent Expirations.

For a full, detailed list, view our report.

Market Trend

  • Increase in Awareness of PVA.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
    • 03.1.1. Product Offerings
      • Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. PVA Drugs Market in the US
    • 06.3.1. Market Size and Forecast
  • 06.4. PVA Drugs Market in Europe
    • 06.4.1. Market Size and Forecast
  • 06.5. Five Forces Analysis

07. Competitive Analysis of Marketed Products

08. Pipeline Snapshot

09. Rate of Incidence and Prevalence

10. Market Segmentation by Types

  • 10.1. Topical Estrogen
    • 10.1.1. Vaginal Cream
    • 10.1.2. Vaginal Tablet
    • 10.1.3. Vaginal Ring
  • 10.2. Systemic Estrogen
    • 10.2.1. Oral Estradiol

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Pfizer Inc.
    • 20.1.1. Business Overview
    • 20.1.2. Business Segmentation
    • 20.1.3. Key Information
    • 20.1.4. SWOT Analysis
  • 20.2. Shionogi & Co. Ltd.
    • 20.2.1. Business Overview
    • 20.2.2. Key Information
    • 20.2.3. SWOT Analysis
  • 20.3. Novo Nordisk A/S
    • 20.3.1. Business Overview
    • 20.3.2. Business Segmentation
    • 20.3.3. Key Information
    • 20.3.4. SWOT Analysis
  • 20.4. Actavis plc
    • 20.4.1. Business Overview
    • 20.4.2. Business Segmentation
    • 20.4.3. Key Information
    • 20.4.4. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global PVA Drugs Market 2013-2018 (US$ billion)
  • Exhibit 3: PVA Drugs Market in the US 2013-2018 (US$ billion)
  • Exhibit 4: PVA Drugs Market in Europe 2013-2018 (US$ billion)
  • Exhibit 5: Global PVA Drugs Market Segmentation by Route of Administration
  • Exhibit 6: Global PVA Drugs Market by Geographical Segmentation 2013
  • Exhibit 7: Business Segmentation of Pfizer Inc.
  • Exhibit 8: Business Segmentation of Novo Nordisk A/S
  • Exhibit 9: Business Segmentation of Actavis plc
Back to Top